Vistagen to report fiscal year 2025 third quarter results and host corporate update conference call on february 13, 2025

South san francisco, calif.--(business wire)--vistagen (nasdaq: vtgn), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will host a conference call and webcast on thursday, february 13, 2025 at 2:00 p.m. pacific time (5:00 p.m. eastern time) to report results for its fiscal year 2025 third quarter ended december 31, 2024, and provide a.
VTGN Ratings Summary
VTGN Quant Ranking